350 rub
Journal №2 for 2011 г.
Article in number:
Wobenzym: correction of ischemic illness hearts and possible mechanisms of action
Authors:
E.S. Antonova, S.N. Bobkova, M.M. Rasulov, O.A. Belikova, M.K. Nurbekov
Abstract:
Influence of a preparation system enzyme therapy  «Wobenzym»  on hemostasis indicators, hemorheology properties of blood, a clinical current of disease is studied at its inclusion in structure of complex therapy of a stenocardia of pressure of II functional class. 30 patients are surveyed. It is established, that wobenzym authentically improves rheology properties of blood at the expense of reduction aggregation abilities erythrocytes and thrombolytic, reduction of viscosity of blood of increase in deformability erythrocyts membranes, optimises activity fibrinolytic and blood curtailing systems, improves a clinical current of a stenocardia and quality of a life of patients which is expressed in reduction of limitation of physical activity, reduction of perception of weight of illness. Under the influence of a preparation the quantity of the general cholesterol, lipoproteins very low density and triglycerides authentically decreases, activity sour lipase of thrombocyts increases. Wobenzym leads to authentic reduction of quantity angina attacks, to reduction of consumed nitroglycerine, promotes tolerance increase to physical activity in the tredmil-test. Application wobenzym as a part of complex therapy sick of a stenocardia of pressure of II functional class is clinically justified, effectively and safely.
Pages: 51-54
References
  1. Системная энзимотерапия / под ред. В.И. Мазурова, А.M. Лала, И. Стернина. СПб.: Моби Дик. 1996. 206 с.
  2. Anderson R.A., Bryson G.M., Parks J.S. Lysosomal acid lipase mutations that determine phenotype in wolman and cholesterol ester storage disease // Mol. Genet. Metab. 1999. V. 68. № 3. Р. 333-345.
  3. Severson D. J., Fletcher T. Characterisation of cholesterol ester hydrolase activites in rabbit and guinea pig aortas // Atherosclerosis. 1978. V. 31. P. 21-32.
  4. Душкин М.И. Макрофаги и атеросклероз: патофизиологические и терапевтические аспекты // Бюллетень СО РАМН. 2006. № 2 (120). С. 47-55.
  5. Меньшиков В.В. Лабораторные методы исследования в клинике. М.: Медицина. 1987. С. 106174.
  6. Богданова С.Н. Клинико-экспериментальное изучение влияния фактора питания на активность лизосомальных гидролаз тромбоцитов и мононуклеарных лейкоцитов при атеросклерозе: Автореф. дисс... канд. М., 1992. 28 с.
  7. Friedwald W.T., Levy R.I., Fredrickson D.S. Estimation of plasma low density lipoprotein cholesterol concentration with use of the preparative ultracentrifuge // Clin Chem. 1972. V. 18. P. 499 - 502.
  8. Климов А.Н. Атеросклероз. В кн. Превентивная кардиология. М.: Медицина. 1977. С. 260 - 271.
  9. Булычев А.Г., Семенова Е.Г., Ассиновская О.А. Влияние агрегации нейтрального красного, акридинового оранжевого и хлористого аммония клетками (сублинии Lsm) на активность лизосомальных гидролаз // Цитология. 1986. Т. 28. № 7. С. 703-711.
  10. Coates P.M., Langer T., Cortner J.A. Genetic variation of human mononuclear leukocyte lysosomal acid lipase activity relationship to atherosclerosis // Aterosclerosis. 1986. V. 62. P. 11-20.